The Safe Clinic is a community based non profit making clinic offering HIV, sexual health and family planning services.
Opening hours:
Mon & Wed : 1.00pm - 4.00pm/5.00p,-8.00pm
Tue : 8.00a.-12.00 noon
Thurs : 12.00 noon - 3.00pm (Women’c clinic)
Fri : 2.00pm - 10.00pm (counseling by appointment only)
Sat : 10.00am - 12.30pm/ 1.30pm - 4.00pm
Closed: on Sundays & Public Holidays
Address: 102,Jalan Thamby Abdullah, Off Jalan Tun Sambantahn 50470, KL, Malaysia.
Tel:03-22602073 | Fax:03-22602069 | Email: thesafeclinic@thesafeclinic.com
It is advised that patient make an appointment before going to the clinic in order to avoid having to wait.
For more information and location of the clinic, please refer to the website.
http://www.thesafeclinic.com
Monday, August 23, 2010
Thursday, July 22, 2010
Thursday, June 24, 2010
Tuesday, May 11, 2010
Monday, January 4, 2010
The Sun: WHO guidelines on HIV drug 'behind time'
http://www.myhealth.gov.my/myhealth/bm/template.jsp?showMe=28&storyid=1260265714420
The Sun
Tuesday, 08/12/2009
WHO guidelines on HIV drug 'behind time'
by Eva Yeong
PETALING JAYA: The new World Health Organisation (WHO) guidelines urging countries to phase out use of major HIV drug Stavudine due to long-term, irreversible side-effects in HIV patients is "behind time".
In fact, Malaysian guidelines have changed since early 2009, said Malaysian Society for HIV Medicine (MaSHM) president dr Christopher Lee.
According to him, countries like UK and Australia have already changed their guidelines, and clinical guidelines in Malaysia have already moved towards lessening the use of the anti-retroviral Stavudine, also known as d4T.
WHO recently announced that countries should phase out the use of d4T, which causes side-effects in HIV patients including wasting and nerve disorder.
It recommended that HIV patients, including pregnant women, should start taking anti-retroviral drugs earlier and for HIV-positive women and their babies to take the drugs while breastfeeding to prevent mother-to-child transmission of the virus.
According to a report by Reuters, Stavudine causes nerve disorder leading to numbness and burning pain in the hands and feet and loss of body fat known as lipoatrophy or wasting.
WHO recommended a move towards less toxic alternatives such as Zidovudine (AZT) or Tenofovir (TDF) which it said are equally effective alternatives.
"We cannot do away with d4T, but we can use less. We are emphasising more on non- Stavudine treatments," said Lee, who advises practitioners in the country to use other alternatives whenever possible.
"The reality is that third world countries still depend on d4T; about half of all Malaysians taking treatment for HIV are still on d4T," he said.
He said phasing out d4T is an extremely expensive exercise. While generic versions of d4T cost about RM25 per month, other alternatives carry three figure price tags.
"To phase it out, we need alternatives. You can?t stop treatment altogether," he said, adding that doctors who prescribe d4T for their patients need to monitor them closely.
He also advised patients on d4T treatment to not panic and cease treatment completely.
"If there are no other options, take d4T, it is still safe to use. If in doubt, discuss with your doctor," he said.
The Sun
Tuesday, 08/12/2009
WHO guidelines on HIV drug 'behind time'
by Eva Yeong
PETALING JAYA: The new World Health Organisation (WHO) guidelines urging countries to phase out use of major HIV drug Stavudine due to long-term, irreversible side-effects in HIV patients is "behind time".
In fact, Malaysian guidelines have changed since early 2009, said Malaysian Society for HIV Medicine (MaSHM) president dr Christopher Lee.
According to him, countries like UK and Australia have already changed their guidelines, and clinical guidelines in Malaysia have already moved towards lessening the use of the anti-retroviral Stavudine, also known as d4T.
WHO recently announced that countries should phase out the use of d4T, which causes side-effects in HIV patients including wasting and nerve disorder.
It recommended that HIV patients, including pregnant women, should start taking anti-retroviral drugs earlier and for HIV-positive women and their babies to take the drugs while breastfeeding to prevent mother-to-child transmission of the virus.
According to a report by Reuters, Stavudine causes nerve disorder leading to numbness and burning pain in the hands and feet and loss of body fat known as lipoatrophy or wasting.
WHO recommended a move towards less toxic alternatives such as Zidovudine (AZT) or Tenofovir (TDF) which it said are equally effective alternatives.
"We cannot do away with d4T, but we can use less. We are emphasising more on non- Stavudine treatments," said Lee, who advises practitioners in the country to use other alternatives whenever possible.
"The reality is that third world countries still depend on d4T; about half of all Malaysians taking treatment for HIV are still on d4T," he said.
He said phasing out d4T is an extremely expensive exercise. While generic versions of d4T cost about RM25 per month, other alternatives carry three figure price tags.
"To phase it out, we need alternatives. You can?t stop treatment altogether," he said, adding that doctors who prescribe d4T for their patients need to monitor them closely.
He also advised patients on d4T treatment to not panic and cease treatment completely.
"If there are no other options, take d4T, it is still safe to use. If in doubt, discuss with your doctor," he said.
Sunday, December 27, 2009
WHO recommends earlier treatment for HIV and a halt in use of Zerit
WHO recommends earlier treatment for HIV and a halt in use of Zerit
http://latimesblogs.latimes.com/booster_shots/2009/11/who-recommends-earlier-treatment-for-hiv-and-a-halt-in-use-of-zerit.html
India weighs options as WHO strikes down cheap HIV drug Stavudine:
http://www.indianexpress.com/news/India-weighs-options-as-WHO-strikes-down-cheap-HIV-drug-Stavudine/552256
http://latimesblogs.latimes.com/booster_shots/2009/11/who-recommends-earlier-treatment-for-hiv-and-a-halt-in-use-of-zerit.html
India weighs options as WHO strikes down cheap HIV drug Stavudine:
http://www.indianexpress.com/news/India-weighs-options-as-WHO-strikes-down-cheap-HIV-drug-Stavudine/552256
Tuesday, December 15, 2009
New HIV recommendations to improve health, reduce infections and save lives
30 November 2009 -- On the eve of World AIDS Day, WHO is releasing new recommendations on treatment, prevention and infant feeding in the context of HIV, based on the latest scientific evidence.
See the link below:
http://www.who.int/mediacentre/news/releases/2009/world_aids_20091130/en/index.html
See the link below:
http://www.who.int/mediacentre/news/releases/2009/world_aids_20091130/en/index.html
Subscribe to:
Posts (Atom)